Background/Objectives: Breast cancer is the most common cancer in women worldwide, requiring strategic efforts to reduce its mortality. This study aimed to develop a predictive classification model for breast cancer mortality using real-world data, including various clinical features. Methods: A total of 11,286 patients with breast cancer from the National Cancer Center were included in this study. The mortality rate of the total sample was approximately 6.2%. Propensity score matching was used to reduce bias. Several machine learning models, including extreme gradient boosting, were applied to 31 clinical features. To enhance model interpretability, we used the SHapley Additive exPlanations method. ML analyses were also performed on the samples, excluding patients who developed other cancers after breast cancer. Results: Among the ML models, the XGB model exhibited the highest discriminatory power, with an area under the curve of 0.8722 and a specificity of 0.9472. Key predictors of the mortality classification model included occurrence in other organs, age at diagnosis, N stage, T stage, curative radiation treatment, and Ki-67(%). Even after excluding patients who developed other cancers after breast cancer, the XGB model remained the best-performing, with an AUC of 0.8518 and a specificity of 0.9766. Additionally, the top predictors from SHAP were similar to the results for the overall sample. Conclusions: Our models provided excellent predictions of breast cancer mortality using real-world data from South Korea. Explainable artificial intelligence, such as SHAP, validated the clinical applicability and interpretability of these models.
1 January 2024 in Journal of Korean Medical Science
Background: Chronic fatigue syndrome (CFS) reduces the health-related quality of life in the working-age population; however, studies have rarely investigated this group. A mixture of Cervus elaphus Linnaeus, Angelica gigas Nakai, and Astragalus membranaceus Bunge (CAA) may be an effective anti-fatigue supplement. However, few clinical trials have explored the anti-fatigue effects of herbal medicines in human participants. Therefore, this study aimed to investigate the effects of the CAA herbal complex on muscle fatigue and endurance capacity in a randomized, placebo-controlled, double-blind trial. Methods: In an 8-week trial, 80 patients with chronic fatigue symptoms were randomly assigned to the CAA (43.5 ± 1.2 years) or placebo group (41.8 ± 1.3 years). Fatigue and cardiorespiratory endurance were measured at baseline, interim, and post-intervention. Fatigue-related blood biomarkers were assessed before and at the end of the intervention. Results: A significant improvement in overall fatigue scores was observed on the fatigue severity scale (p = 0.038), multidimensional fatigue inventory (p = 0.037), and 24-hour visual analog scale (p = 0.002) in the CAA group compared to those in the placebo group. Fatigue improvement was observed in the CAA group, as well as physiological variables, such as increased maximal exercise time to exhaustion (p = 0.003), distance until exhaustion (p = 0.003), and maximum oxygen consumption (p = 0.039). Conclusion: CAA positively and significantly affected fatigue and cardiorespiratory endurance in patients with chronic fatigue, suggesting the potential use of herbal supplements for treating chronic fatigue. Trial registration Clinical Research Information Service (CRIS, https://cris.nih.go.kr/ ): KCT0005613.
Given curcumin's antioxidant properties, this study aimed to determine the effectiveness and safety of Theracurmin Super supplementation in mitigating exercise-induced oxidative stress in healthy adults. Seventy-one healthy adults participated in this study, which was conducted at Seoul National University from April 2022 to March 2023. Eligibility was determined during visit 1 through maximum oxygen consumption assessed using the Bruce Treadmill protocol. In visit 2, participants were randomly allocated to either the Theracurmin Super supplement group (TG, n = 36) or Placebo supplement group (PG, n = 35). Over 8 weeks, participants consumed Theracurmin Super (curcumin, 120 mg/day) or Placebo (curcumin, 0 mg/day) twice daily and visited the laboratory four times. Various parameters, including body composition, vital signs, nutrition quotient for adults, cardiorespiratory endurance, blood biomarkers, and adverse events, were assessed at each visit. Statistical analyses included per-protocol analysis, t-tests for group and within-group differences, and two-way ANOVA. In week 8, blood biomarkers linked to oxidative stress, including TBARs, MDA, 8-OHdG, SOD, TOS, and OSI, showed significant group- and week-related interactions (total oxidant status: resting state P = 0.021; oxidative stress index, resting state P = 0.020, end of exercise, P = 0.013). Notably, the TG showed a significant decrease in total oxidant status (resting state P = 0.041) and oxidative stress index (resting state P = 0.018 and end of exercise P = 0.008) between weeks 0 and 8. However, MDA and 8-OHdG levels did not show statistically significant changes. Theracurmin Super effectively reduced oxidative stress before and after exercise, highlighting curcumin's promising role in managing oxidative stress. Significant improvements in TOS and OSI were observed, although changes in MDA and 8-OHdG levels were not statistically significant. Further research could provide insights into these mixed results across different oxidative biomarkers. Clinical Research Information Service (CRIS): KCT0008731.
Age-related macular degeneration (AMD) is a leading cause of irreversible visual impairment among older adults. Despite the accumulation of evidence linkin
16 November 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: Cancer survivors have an elevated cardiovascular disease (CVD) risk. Existing evidence is often limited by cross-sectional designs or single-cancer focus, hindering systematic comparisons across different cancer types. We examined cancer type-specific patterns of association between cardiovascular risk factors and incident CVD. Methods: This nationwide cohort study utilized the Korea-Clinical Data Utilization Network for Research Excellence database, including 148,537 survivors of breast, colorectal, gastric, liver, or lung cancers (2012–2021). Primary outcome was incident CVD (ischemic heart disease [IHD] or stroke). Cause-specific Cox models were used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs), with death as a competing risk. Results: Age, hypertension, and diabetes were significant predictors of incident CVD across all cancer types. Heavy smoking was associated with a high CVD risk in survivors of breast (aHR, 1.93; 95% CI, 1.29–2.89) and colorectal cancers (1.42; 1.26–1.60). Severe obesity (body mass index ≥ 30 kg/m²) was associated with a high CVD risk in survivors of breast (1.25; 1.07–1.47) and liver cancers (1.32; 1.03–1.69), and with incident IHD across all cancer types, but most strongly in liver and lung cancers. Incident stroke was more strongly associated with advanced tumor stage (aHR range, 1.59–2.13) than with obesity. Conclusions: Cardiovascular risk factor associations vary by cancer type and CVD subtype, supporting the use of tailored, cancer type-specific risk-reduction strategies in survivorship care. Impact: These findings provide an evidence base for cancer-specific cardiovascular risk stratification in survivorship care.